TC BioPharm Files Definitive Proxy Statement

TL;DR

TC BioPharm just dropped its proxy statement. Shareholders, get ready to vote.

AI Summary

TC BioPharm (Holdings) plc filed a definitive proxy statement (DEF 14A) on June 7, 2024. The filing pertains to the company's annual meeting and related corporate governance matters. The company is incorporated in X0 and its fiscal year ends on December 31st.

Why It Matters

This filing provides shareholders with essential information regarding voting rights, director nominations, and other corporate decisions to be made at the company's upcoming meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or significant corporate actions that would immediately impact risk.

Key Players & Entities

• TC BioPharm (Holdings) plc (company) — Registrant
• 0001493152-24-023099 (filing_id) — Accession Number
• 20240607 (date) — Filing Date

FAQ

Filing Documents

• formdef14a.htm (DEF 14A) — 350KB
• formpre14a_001.jpg (GRAPHIC) — 4KB
• image_001.jpg (GRAPHIC) — 670KB
• image_002.jpg (GRAPHIC) — 685KB
• 0001493152-24-023099.txt ( ) — 2223KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 TC BioPharm (Holdings) plc (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 TC BioPharm (Holdings) plc (a public limited incorporated and registered in Scotland under the Companies Act 2006 with registered number SC713098) Maxim 1,2 Parklands Way, Holytown, Motherwell, Scotland, ML1 4WR June 7, 2024 Dear Shareholder, 2024 Annual General Meeting of the shareholders of TC BioPharm (Holdings) plc (the “AGM” or “Meeting”) We are pleased to provide details of the AGM of TC BioPharm (Holdings) plc (the “ Company ”) to be held as a physical meeting at 15:00 UK (BST) time on Monday July 1, 2024 at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom. The formal notice of AGM set out in this document (the “ Notice of AGM ”) contains, on the following page, the shareholder resolutions to be proposed and voted on at the AGM. For the purposes of the AGM under our current Articles of Association, a quorum will be present if two shareholders of the Company entitled to vote are present in person or by proxy at the General Meeting, However, we will require a quorum of at least 33 1⁄3 percent in number of the issued shares entitled to vote on the business to be transacted at the General Meeting to be present in person or by proxy, to comply with the Nasdaq Stock Market LLC (“Nasdaq”) rules applicable to us as a U.S. domestic registrant. We are holding our AGM as a physical meeting of shareholders and are therefore unable to offer shareholders online voting facilities during the AGM. It is important that shareholders do still cast their votes in respect of the business of the AGM. We strongly encourage all shareholders to complete and return a proxy form appointing the Chair of the Meeting, as proxy. Further information on how to appoint a proxy is detailed from pages one to six of this Notice of AGM. In order to allow the voting preferences of all shareholders to be taken into account, a poll will be conducted on all resolutions proposed in this Notice of AGM. The results of the voting will be posted on the Company’s website as soon as practicable after the Meeting. Action to be taken Ordinary Shareholders If you are a holder of ordinary shares in the Company, please vote on the resolutions by appointing a proxy in accordance with the instructions set out from pages one to six of the Notice of AGM. A form of proxy for use by ordinary shareholders at the AGM is enclosed. You are strongly encouraged to appoint the Chair of the AGM as your proxy. You are advised to complete and return the form of proxy in accordance with the instructions printed on it so as to arrive at the Company’s registered office (Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR) marked for the attention of the Company Secretary as soon as possible, but in any event no later than 15:00 (UK time) (10:00 Eastern Time) on June 27, 2024. CREST members who wish to appoint a proxy or give an instruction through the CREST electronic proxy appointment service may do so by using the procedures described in the CREST manual. ADS Holders If you are a holder of ADS in the Company, you will not be able to attend the ordinary shareholder’s meeting as it is a meeting of ordinary shareholders, but you will be able to cast your vote on the resolutions in accordance with the Depositary Agreement with Bank New York Mellon who holds on your behalf, via its trustee, the ordinary shares which underlie your ADSs and which you are able to cast votes in respect of. Please vote on the resolutions in accordance with the instructions set out from pages one to six of the Notice of AGM. A form of proxy for use by ADS holders will be sent to the brokerage firm, bank or nominee through which you hold your ADS by the Depositary and the Depositary will accumulate all votes and pass them onto the Company in a summary form for adding into the polled votes. Recommendation You will find an explanatory note accompanying each of the various resolutions which are set out in the Notice of AGM. Your Board consider that the proposed resolutions in the Notice of AGM are in the be

View Full Filing

View this DEF 14A filing on SEC EDGAR